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Abstract. 
The present work aims to synthesize novel diclofenac derivatives containing L-alanine moiety. The synthesized c
ompounds docked into the active site to discover validated inhibitors of cyclooxygenases (COX-1 and COX-2). 
The calculations in-silico were predicted that, the compound with lowest energy of docked poses was interacted 
with residues of active site, perhaps could be making them possible selective inhibitors against (COX-2) and phy
siologically  active. The binding score of compound compared with reference drug, and show extensive interacti
ons with the targets, which may consider it a suitable selective inhibitor against   (COX-2). 
Keywords:  Alanine, Diclofenac, COX, DOCKING, ADMET. 
 
1. Introduction.  
Non-steroidal anti-inflammatory drugs (NSAIDs) are widely employed in musculoskeletal disease, as 
well as their anti-inflammatory properties [1].  After widely evaluation, NSAIDs is efficacy in different clinical 
setting, and act as COX inhibitor (COX-1 and COX-2) through inhibiting the production of prostaglandins (PGs) 
[2-4]. Diclofenac is a one from famous available members of these drug’s class under current clinical usage [5], 
and suffer from a common toxicity of gastrointestinal drawback, due to inhibition non-selectively of 
cyclooxygenase enzyme [6–8], also, its display anti-microbial [9-11], ulcerogenic, analgesic, anti-inflammatory, 
lipid peroxidation [12,13],  antitumor [14] and inhibitor  formation of transthyretin amyloid fibril properties [15]. 
Also, the alaninyl derivatives especially containing amide and thioamide moieties possess diverse biological 
activities, such as anti-inflammatory, anti-tumor and antimicrobial activity [16-18]. Furthermore, substituted 4-
quinazolinone have antimicrobial[19], antifolates, antitumor[20], antimalarial[21], CNS depressant, 
anticonvulsants [22], anti-inflammatory [23] and analgesic activities[24]. Hence, the  present  study  aims  to  
synthesis new series of alanyldiclofenac derivatives acting as new potent anti-inflammatory agents without 
ulcerogenic effects, followed by molecular modeling to identify  the  structural  features  of  these  new  series.  
The molecular docking was preformed, to predict the correct binding  geometry for each ligand at the active site, 
which may be support that postulation, its active compounds  may be act as a new NASIDs.  
2. Results and discussion. 
2.1. Chemistry. 
The starting compound of 2-(4-(N-(4-bromophenyl)sulfamoyl)-phenyl)acetyl chloride 3 was carried out 
according steps depicted in (Scheme 1).  
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Scheme 1:regent and conditions; i- H2O/ dil-Hcl., ii-SOCl2,
iii-L-Ala/fussion, iv-L-Ala/THF/TEA.
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Compound 4 was prepared with two strategy to afford (L)-2-(2-(2-(2,6-dichlorophenylamino) 
phenyl)acetamido)propanoic acid (4). The first strategy:  by coupling of  3 with L-alnine in THF/TEA/H2O 
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media to give 4, another strategy; through fused 2 with amino acid to afford the desired compound 4.  The  IR  
spectrum of  compound  4  indicated  that  presence  of  a OH and NH function as broad band   (3204  cm -1),  
and  its  the 1HNMR  spectrum showed a singlet at (δH 12.00 ppm) due to OH protons of carboxylic. In order to 
establish enantiomeric purity of isolated compound, the  specific  rotation  values  were  determined,  which  
remained  unchanged  after  repeated  crystallization  for  several  times.   Also, enantiomeric  excess  (ee)  and 
diastereoisomeric excess (de) values  were determined, these values based on the stereo configuration of amino 
acid   of   amide   part   of   products   4,  which obtained through  nucleophilic  addition  of  free  amino  acids  
on diclofenac.  Also,  from  TLC  analysis,  the  optical purity  of  the  resulting  compounds  was  greater  than 
97%. Thus, as expected, stereo chemical configuration at α-carbon atom of the acid was practically unaffected 
and this synthetic transformation from chiral α-amino acid could be applied to a wide range of compounds 
without undergoing any significant loss of optical  activity.   
    
2.2. Biological activity: 
2.2.1. anti-inflammatory activity 
The screening of the anti-inflammatory activity in vivo for the synthesized compounds were preformed,  using 
the functional  model  of Carrageenan-induced rat paw edema assay[27], this test is a nonspecific inflammation 
but is highly sensitive to NSAIDs.  Indomethacin and Diclofenac is one of the most potent NSAIDs, and was 
used as a reference drug, the percentage reduction of tested compounds for edema in comparison with the control 
was calculated (Table 1).  The percentage edema reduction for the tested compounds compared with the control 
and reference drugs groups, showed significant value ranged (54.19%) for compound 4, (Table 1). The tested 
compound showed, nearly reduction percentage of edema compared with reference drugs (Table 1). 
 
Table 1: Anti-inflammatory effect   of   synthesized compounds on carrageenan- induced paw  edema in rats 
after1, 2,3 and 4h of test drug administration. 
 
 
 
 
 
 
 
*   Values are expressed as mean ± S.E.M (n = 6) and analyzed by ANOVA. Dose= 20 mg/kg. 
** Percentage Inhibition of paw edema from control group  
a)  Statistically significant at the corresponding time (p < 0.05). 
 
2.2.2. Analgesic activity 
The analgesic activity of tested compounds was evaluated by using tail-flick test in mice [28], with the 
same dose as used for anti-inflammatory activity,  the percent protection of  the drugs was calculated in Table 2. 
The compound under investigation, showed analgesic activity in 45.78%., and showed analgesic potency nearly 
the analgesic effect of diclofenac sodium  (Table 2). 
Table 2: Analgesic activity using tail-flick test and Ulcer gastric of rats for tested compounds. 
*    Values are expressed as mean ± S.E.M (n = 6) and analyzed by ANOVA. Dose= 20 mg/kg. 
** Percentage protection  tail flick   tail   from control group  
a)  Statistically significant at the corresponding time (p < 0.05). 
 
 
 
% Inhibition ** 
 
Volume of paw edema (in ml)*       Compounds 
4 h 3 h 2 h 1 h 
_ 125.1±11.12 119.3±12.04 105.2±10.98 71.69±9.941 Control 
67.49 40.67±4.801 a 28.28±3.789 a 16.73±2.886 a 12.76±2.795a Indomethacin  
65.17 43.56±5.306 a 27.77±2.123 a 19.16±1.23 a 12.55±1.35 a Diclofenac 
54.19 52.32±3.35 a 45.75±6.04 a 25.27±2.156 a 18.36±1.21 4 
Ulcerogenic index 
%  protection 
** 
Analgesic activity*       Compounds 
Ulcer 
Number 
Ulcer 
severity 
90 Min 60 Min 30 Min Base line 
0.0 0.0 _ 5.340±0.356 4.320±0.489 3.750±0.256 3.640±0.445 Control 
11.8 ±0 
.985 
22.4 
±1.652 60.96 
13.68±0.471a 10.28±0.873a 7.960±0.823 4.700±0.452 Indomethacin  
0.0 0.0 47.95 10.26±1.121 7.580±0.725 6.240±0.623 5.000±0.512 Diclofenac  
0.0 0.0 45.78 9.850±0.735 7.680±0.712 6.125±0.513 4.250±0.432 4 
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2.2.3. Acute ulcerogenesis 
The compounds were screened for gastric irritation activity. The ulcerogenic effect of Indomethacin and 
newly synthesized compounds were studied at 20 mg /kg in rats. The data in table 2, the tested compounds  
exhibited  significant reduction in  ulcerogenic  activity  compared with  the indomethacin (standard drug),  
which   showed   high   severity   index   of 4.50 ± 0.316,  this data confirmed that, these compounds showed 
negligible ulcerogenic effect, and may be considered as safer drugs for treating inflammation conditions. 
 
2.2.4. Determination of acute toxicity (LD50) 
The LD50 for diclofenac sodium and isolated new compound 4 was screened, all rats were alive during 
the 24 h of observation when treated with up to 500 mg\ kg for different compounds, and did not show a visible 
signs of acute toxicity, furthermore, Therapeutic  index  was  calculated:  as following ( LD50 \ ED50). The  
LD50 of isolated new compound 4 was 820 mg\kg with therapeutic  index 41.5, LD50 compared with value  530 
mg\kg for diclofenac sodium was (therapeutic  index= 25). So, the new isolated compound 4 have higher 
therapeutic index compared with diclofenac sodium, and may be appear to be relatively less toxic as  anti-COX 
agents. 
2.3. Molecular Modeling studies. 
2.3.1. Conformational analysis 
It is obvious that, a possibility existence of the synthesized amino acid derivatives 4 in L and D 
stereoisomer forms. In trying to achieve better insight into the molecular structure of  the most preferentially 
steroisomer forms for its compounds, conformational analysis of the target compounds has been performed using 
the MMFF94 force-field[29]  (calculations  in  vacuo,  bond  dipole option for electrostatics, PolakeRibiere 
algorithm, RMS gradient of 0.01 kcal/A mol) implemented in MOE [30]. The most stable conformer for 4 were 
fully geometrical optimized with molecular orbital function PM3 semi-empirical Hamiltonian molecular orbital 
calculation MOPAC 7 package [31].  The computed molecular parameters, total energy, electronic energy, heat 
of formation, the highest occupied molecular orbital (HOMO) energies, the lowest unoccupied molecular orbital 
(LUMO) energies and the dipole moment for studied compounds were calculated (Table 3).  
The calculated molecular parameters have been used to investigate the most stable stereoisomer form 
(table 3), and showed the most stable stereoisomer is the (L) form, this may be explained by slightly reduces its 
calculated energy, and leads to predominance this structures (L) form over (D) forms.  The lowest minimization 
energy for the for new isolated structures exhibited (Fig .1), The higher HOMO energy  values show  the  
molecule  is  a  good  electron  donor, in other hand, the lower HOMO energy values indicate that, a weaker 
ability of the molecules  for donating electron.  LUMO energy presents the ability of a molecule for receiving 
electron [32], (Table 3). 
Table 3:   The Optimized Calculations Energies at PM3 molecular orbital for 1-4. 
 L 
 
Cpd E Eele HF IP HOMO LUMO µ 
1 -67011.1 -415646 -70.83 6.79 -6.09 -0.09 7.96 
3 -74214.3 -403091 -2.454 8.75 -8.15 -0.31 3.17 
4 -94548.3 -657542 -90.49 8.61 -8.21 -0.30 4.23 
 D 
1 -68011.1 -425646 -71.83 6.79 -6.79 -0.09 7.96 
3 -76214.3 -473091 -2.454 8.75 -8.75 -0.41 3.17 
4 -97547.9 -696306 -92.68 8.79 -8.79 -0.48 4.30 
E: Total energy (kcal/mol), E-ele:Electronic energy (kcal/mol),HF: Heat of formation (kcal/mol), IP: Ionization potential 
energy(kcal/mol), HOMO: Highest Occupied Molecular Orbital(eV), LUMO: Lowest Occupied Molecular Orbital(eV), µ: 
Dipole moment(Deby). 
 
2.3.2.  ADMET factors profiling:  
Oral bioavailability considered playing an important role for the development of bioactive molecules as 
therapeutic agents. Many potential therapeutic agents fail to reach the clinic, because of their ADMET 
(absorption, distribution, metabolism, elimination and toxic) Factors. Therefore, a computational study for 
prediction of ADMET properties of the molecules was performed for tested compounds 1-4, by the 
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determination of topological polar surface area (TPSA), a calculated  percent  absorption  (%ABS) which was 
estimated  by Zhao et al. equation [33], and ‘‘rule of five’’  formulated by Lipinski[34],  which established that, 
chemical compound could be an orally active drug in humans, if no more than one violation of the following 
rule: i) ClogP (partition coefficient between  water  and  octanol) < 5, ii)  number  of hydrogen bond donors sites  
≤ 5, iii) number of hydrogen bond acceptors sites  ≤ 10, iv),  molecular  weight  <500 and  molar refractivity 
should be between 40-130.   In addition, the total polar surface area (TPSA) is another key property linked to 
drug bioavailability, the passively absorbed molecules with (TPSA>140) have low oral bioavailability [35].  All 
calculated descriptors were performed using MOE Package [30], and their results were disclosed in (Table 4). 
Our results revealed that,  the CLogP (factor of the lipophilicity [36] was less than 5.0 except 3 and 20-23, the 
molecular weight (MW< 500), hydrogen bond acceptors between (2-5), hydrogen bond donors between (1-3) 
and molar refractivity values ranged (~73-93),this data show these compounds fulfill Lipinski’s rule. Also, the 
percent in ranged between (~ 82-99%).  
Table4:  Pharmacokinetic parameters important for good oral bioavailability of  compounds 1,3 and4: 
CPD HBD HBA LogP V Vol. TPSA %ABS Log S mr ∆E η S χ σ ω 
1 1 2 4.202 0 150 29.1 99.305 -4.914 73.18 6.705 3.352 0.298 -3.44368 3.443 1.768 
3 1 2 5.131 1 132.25 29.1 99.305 -5.661 75.46 8.33 4.169 0.239 -4.58144 4.581 2.517 
4 3 5 3.82 0 154.625 78.43 82.286 -5. 79.32 8.313 4.156 0.240 -4.456 4.456 2.389 
TPSA: Polar surface area (A°2), %ABS: Absorption percentage, Vol: Volume (A3), HBA: Number of hydrogen bond 
acceptor, HBD: Number of hydrogen bond donor,  V: Number of violation from Lipinski’s rule of five., Log P: Calculated 
lipophilicity., Log S: Solubility parameter, mr: Molar Refractivity, ∆E: Energy Gaps(eV), η: Hardness(eV), S: Softness(eV), 
χ : Electronegativity (eV), σ: chemical potential (eV),  ω:Electrophilicity (eV). 
 
The HOMO and LUMO of a molecule play important roles in intermolecular interactions[37], through 
the  interaction  between  the  HOMO  of  the  drug  with  the LUMO of the receptor and vice versa. The 
interactions stabilized inversely with energy gap between the interacting orbitals.  Increasing HOMO energy and 
decreasing LUMO energy in the drug molecule lead to enhancement stabilizing interactions, and hence, binding 
with the receptor. Furthermore, the global and local chemical reactivity descriptors for molecules have been 
defined (table 4), like softness (measures stability of molecules and chemical reactivity [38]), hardness 
(reciprocal of softness), chemical potential, electronegativity (strength atom for attracting electrons to itself), 
electrophilicity index (measuring lowering energy due to maximal flowing electron between donor and acceptor) 
[38-43]. The results showed, the higher potency compound 4 have, higher electrophilicty, higher hardness, lower 
energy gap, lower softness, lower electronegativity and lower dipolemoment (Table 3), which may be explained 
the highest anti-inflammatory affinity of  its compounds (Table 4).    
2.3.3. Docking studies: 
In brief, two isoforms of COX protein are known: COX-1, is responsible for the physiological 
production of prostaglandins, which is expressed in most tissues; and COX-2, is responsible for the increasing 
production of prostaglandins during process of inflammation, which is induced by endotoxins, cytokines and 
mitogens in inflammatory cells [44]. Recently, from analysis of X-ray cocrystal of arachidonic acid with COX-2 
showed that, carboxylate coordinated with Tyr-385and Ser-530[45], as well as the action of NSAIDs, through 
interaction carboxylate group with Tyr-385 and Ser-530, which stabilize the negative charge of the tetrahedral 
intermediate [46], and demonstrated that, Tyr-385 and Ser-530 have a structural and functional evidence for the 
importance of them in the chelating of the ligands[45].  Molecular docking of the synthesized compounds into 
the active site of COX was performed, in order to understanding obtained biological data on a structural basis, 
through rationalized ligand–protein interaction behavior.  All calculations for docking experiment preformed 
with MOE 2008.10 [30]. The tested compounds were evaluated in silico (docking), using X-ray crystal structures 
of COX-1 (ID: 3N8Y)[46] and COX-2 (ID: 1PXX) [45] complexes with Diclofenac as inhibitor.  The tested 
compounds docked into active sites of both enzymes COX-1 and COX-2. The active site of the enzyme was 
defined to include residues within a 10.0 Å radius to any of the inhibitor atoms. MOE scoring function of the 
most stable docking model for tested compounds applied to evaluate the binding affinities between the inhibitors 
complexes with (COX) active site, Table (5).  
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Table5: Docking energy scores (kcal/mol) derived from the MOE for new isolated ligands: 
COX-1 
Cpd. dG Int. H.B. Eele Evdw 
1 -9.37872 1.94646 -15.2523 -9.37872 -22.4701 
4 -8.4911 1.378388 -19.46 -10.4911 -26.1386 
 COX-2 
1 -98.8173 -22.018 -14.9099 -7.95803 -15.1421 
4 -123.166 -26.6146 -20.3448 -8.14974 -20.5073 
d.G.: free binding energy of the ligand from a given conformer, Int.: affinity binding energy of hydrogen bond  interaction 
with receptor, H.B.: Hydrogen bonding energy between protein and ligand. Eele: the electrostatic interaction with the 
receptor, Evdw: van der Waals  energies between the ligand and the receptor.  
 
 
The complexes were energy-minimized with an MMFF94 force field [29] until the gradient 
convergence 0.05 kcal/mol reached.  The most active compounds docked successfully into the COX-1 active 
site.  
 
 
Fig. 2. The compound (1) Docked into the active site of  COX-2. using MOE tool. 
.the binding energies obtained from modeled of diclofenac 1 and 4 into active site of COX-2 are (~ 98.8 
and -123.16) , respectively, (Fig. 1 and 2 , table 5) , reference drug (1) and compound 4 stabilized in binding 
pocket by adjusting two phenyl ring in perpendicular with each other. In addition, the compounds (1) and (4) 
were arranged with binding pocket by perpendicular adjusting of chlorophenyl ring of ligands 1 and  4 with 
phenyl ring of Tyr-385. 
 
Fig. 2. The compound (4) Docked into the active site of  COX-2. using MOE tool. 
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The results obtained  clearly  reveals  that,  the  amino  acid  residues  close  to  the  reference  
molecules diclofenac  are mostly the same as those observed in the currently isolated synthesized compounds 
complexes with protein (Fig. 1 and 2). Compared with the original inhibitor 1, the higher binding energies and 
binding process interaction observed for 4 in COX-2, and the lower binding energies of isolated compounds in 
COX-1, this results indicate that, this compound 4 act as selective inhibitor against COX-2 and considering most 
suitable more suitable COX-2 inhibitor than diclofance, this could probably due to the presence hydrophobic 
amino acid residue in prepared ligand.   
2. Conclusion.  
A series of Diclofenac derivatives containing L-alanine moiety (4) synthesized. The comparative docking 
experiment was carried out on isolated synthesized compound (4) compared with reference molecules 1, which 
indicate that, this compound was stabilized in the binding pocket of COX with a similar binding mode of 
diclofenac, and have higher binding score, and showed suitable selective inhibitors against COX-2. The 
compounds subjected to ADMET profile, which theoretically reveled that, this compounds should present good 
passive oral absorption. The ulcerogenic studies screened for isolated compound 4, and showed negligible 
ulcerogenic effect with higher safety and better therapeutic index than diclofenac, molecular docking studies 
supported with ulcerogenic effect, and understanding the various interactions for ligands and active sites of 
enzyme help to design novel potent selective COX-2 inhibitors. 
4. EXPERMINTAL: 
4.1. Instrumentation and materials: 
Melting points taken on a Griffin melting point apparatus and are uncorrected. Thin layer chromatography 
(Rf) for analytical purposes was carried out on silica gel and developed. Benzidine, ninhydrin, and hydroxamate 
tests used for detection reactions. The IR spectra of the compounds recorded on a Perkin–Elmer 
spectrophotometer model 1430 as potassium bromide pellets and frequencies reported in cm-1. The  NMR 
spectra were observed on a Varian Genini-300 MHz spectrometer and chemical shifts (δ) are in ppm. The mass 
spectra recorded on a mass spectrometer HP model MS–QPL000EX (Shimadzu) at 70 eV. Elemental analyses 
(C, H, N) were carried out at the Microanalytical Centre of Cairo University, Giza, Egypt.  
4.2. Synthesis: 
4.2.1.   2-[(2,6-Dichlorophenyl)amino]phenyl  acetyl  chloride (3) . 
Prepared by reported method and directly used in the next step (40, 41). 
4.2.2. General procedures for synthesis L-aminoacid  derivatives (4).   
Path 1: 
A mixture of (0.01 mol) L-alanine with (0.01 mol) of 2-(2-(2,6-dichlorophenyl-amino)phenyl)acetic acid 2,  
was fused at 280°C  in an oil bath for 15 min., the fused mass was dissolved in ethanol and poured onto cold 
water, the solid obtained was recrystallized from ethanol to give compound 4  
Path 2: 
The mixture of  (0.01 mol) L-alanine with 2-[(2,6-dichlorophenyl)amino]phenyl  acetyl  chloride (3) were  
dissolved in mixture of  water (25 ml) and THF (15ml), triethylamine  (2ml)   was added, followed by  portion-
wise addition of acid chloride (3; 0.01 mmol)  during  30  min,  temperature  of  the  reaction  mixture  was kept 
at 10°C  during the addition.  Stirring continued for 3 h at 10°C.  THF  was  removed  by concentration  of  the  
reaction  mixture  under  reduced  pressure; water (30 ml) was added and acidified with 1 N HCL to pH =5. The 
crude products filtered and re-crystallized from ethanol.  The product 4 was chromatographically homogeneous 
by iodine and benzidine development.  Brown crystal : yields=81%; Rf= 0.35 (CHCl3/EtOH=3/1); mp: 149-51  
°C;      =+49.1° (EtOH); IR (KBr cm-1) ν; 3204 broad band (OH,NH), 3095 (CHarom.), 2854 (CHali.), 
1730(CO),1612 and 1567(CONH) cm1; 1H NMR (300 MHz, CDCl3)  δ= 12.00 (s, 1H-OH), 7.72 – 7.05 (m, 7H-
Ar-H), 7. 01 (s, H-NH-Dic.), 6.83(s, H-NH-Ala), 3.85(s, 2H, CH2-Dic.), 0.06-0.03 (m, 4H-Ali-H); Anal./Calcd.  
for  C17H16Cl2N2O3 (366):  C  (55.51%),  H  (4.32%),  N  (7.56%).   Found: C (55.60);  H (4.39); N, (7.33).    
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4.3. Molecular Modeling Study: 
4.3.1. Generation of Ligand and Enzyme Structures. 
4.3.1.1. Selection of COX structures. 
Docking study was carried out for the target compounds into (COX-1 (ID: 3N8Y) and COX-2 (ID: 1PXX) 
using MVD,4.0  and MOE,10. The crystal structure of the (COX) complexes with (1), which a selective 
inhibitor of COX-2 in co-crystallized form in the active site of the receptor. From X-ray crystal structure studies 
of the COX enzyme, the mouse enzyme expected to be very similar to the human [19], and used as model for 
human COX enzyme. 
4.3.2. Preparation of Small Molecule: 
Molecular modeling of the target compounds built using MOE, and minimized their energy with PM3 
through MOPAC. Our compounds introduced into the (COX) binding site accordance the published crystal 
structures of (1) bound to kinase.  
     4.3.3. Stepwise Docking Method: 
4.3.3.1. MOE Stepwise 
The crystal structure of the (COX) with a Diclofenac (1) as inhibitor molecule, was used for the 
receptor molecule, Water and inhibitor molecules were removed, and hydrogen atoms were added. The 
parameters and charges assigned with MMFF94x force field.   After alpha-site spheres were generated using the 
SITE FINDER module of MOE.  The optimized 3D  structures of molecules  were  subjected  to generate 
different poses of  ligands  using  triangular  matcher  placement  method, which generating poses by aligning 
ligand triplets of atoms on triplets of alpha spheres representing in the receptor site points, a random triplet of 
alpha sphere centers is used to determine the pose during each iteration. The pose generated rescored using 
London dG scoring function. The poses generated were refined with MMFF94x forcefield, also, the solvation 
effects were treated. The Born solvation model (GB/VI) used to calculate the final energy, and the finally 
assigned poses assigned a score based on the free energy in kJ/mol 
4.4.  Pharmacology. 
4.4.1. Determination of acute toxicity 
 The acute toxicity and lethality (LD50) for the new isolated compound estimated in albino mice (25–
30 g). In a preliminary test, animals in groups of three, received one of 300, 500, 600 or  700  mg\ kg  for the 
tested compounds and diclofenac. Animals observed for 24 h for signs of toxicity and number of deaths. The 
LD50  calculated as the percentage mortality in each group was determined 24 h after administration[44].  
4.4.2.  Acute ulcerogenesis. 
 The studies carried out on healthy Albino rats at a dose 20 mg\ kg. The animals were divided into 
different groups of six each, group I served as control and received vehicle only, groups II received pure 
indomethacin 20 mg\kg, the other groups were administered test compounds in dose molecularly equivalent to 
20 mg\ kg of indomethacin. Before 24 h administration of the tested compounds, Food not water removed; the 
rats fed normal diet for 17 h and then sacrificed after the drug treatment. The stomach removed and opened 
along the greater curvature, washed with distilled water and cleaned gently by dipping in saline. The mucosal 
damage examined by means of a magnifying glass. For each stomach, the mucosal damage was assessed 
according  to  the  following  scoring  system[45].   
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